BioCryst Pharmaceuticals BCRX Lease Liability Payments - Remainder of Fiscal Year
Lease Liability Payments - Remainder of Fiscal Year at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's lease liability payments - remainder of fiscal year.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's lease liability payments - remainder of fiscal year?
- BioCryst Pharmaceuticals (BCRX) reported lease liability payments - remainder of fiscal year of $1.11M in Q1 2026.
- How has BioCryst Pharmaceuticals's lease liability payments - remainder of fiscal year changed year-over-year?
- BioCryst Pharmaceuticals's lease liability payments - remainder of fiscal year decreased by 34.3% year-over-year, from $1.69M to $1.11M.
- What does lease liability payments - remainder of fiscal year mean?
- The contractual cash obligations for operating and finance leases due within the remaining months of the current fiscal year. This provides a short-term view of the company's fixed lease commitments. It is a critical component for assessing near-term liquidity and cash flow requirements.